Alkyl hydroperoxide reductase: a candidate Helicobacter pylori vaccine. (Q47888429)

6 February 2018

title

Alkyl hydroperoxide reductase: a candidate Helicobacter pylori vaccine. (English)

1 reference

6 February 2018

1 reference

Avril A O'Riordan

1

1 reference

6 February 2018

Veronica Athie Morales

2

1 reference

6 February 2018

Linda Mulligan

3

1 reference

6 February 2018

Nazia Faheem

4

1 reference

6 February 2018

Henry J Windle

5

1 reference

6 February 2018

Dermot P Kelleher

6

1 reference

6 February 2018

language of work or name

English

0 references

publication date

15 April 2012

1 reference

6 February 2018

published in

Vaccine

1 reference

6 February 2018

volume

30

1 reference

6 February 2018

issue

26

1 reference

6 February 2018

page(s)

3876-3884

1 reference

6 February 2018

Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

An international association between Helicobacter pylori infection and gastric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Recrudescence of Helicobacter pylori after apparently successful eradication: novel application of randomly amplified polymorphic DNA fingerprinting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Antibiotic resistance problems with Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Helicobacter pylori treatment in the era of increasing antibiotic resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Epidemiology of Helicobacter pylori infection and gastric cancer in Asia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Quantifying the population impact of a prophylactic Helicobacter pylori vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Helicobacter pylori virulence and genetic geography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Infection with Helicobacter pylori is associated with protection against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Childhood Helicobacter pylori infection and growth impairment in developing countries: a vicious cycle?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Clearance of Helicobacter pylori Infection and Resolution of Postimmunization Gastritis in a Kinetic Study of Prophylactically Immunized Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Further development of the Helicobacter pylori mouse vaccination model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

The design of vaccines against Helicobacter pylori and their development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Expression of Helicobacter pylori AlpA protein and its immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Cloning and expression and immunogenicity of Helicobacter pylori BabA2 gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Evaluation of superoxide dismutase from Helicobacter pylori as a protective vaccine antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Therapeutic immunisation against Helicobacter infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Protective efficacy of anti-Helicobacter pylori immunity following systemic immunization of neonatal mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Development of a mouse model of Helicobacter pylori infection that mimics human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Essential thioredoxin-dependent peroxiredoxin system from Helicobacter pylori: genetic and kinetic characterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Immune response to a 26-kDa protein, alkyl hydroperoxide reductase, in Helicobacter pylori-infected Mongolian gerbil model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

The 26-kilodalton, AhpC homologue, of Helicobacter pylori is also produced by other Helicobacter species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Lipid peroxidation as a source of oxidative damage in Helicobacter pylori: protective roles of peroxiredoxins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Oxidative-stress resistance mutants of Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Association of Helicobacter pylori antioxidant activities with host colonization proficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

The antioxidant protein alkylhydroperoxide reductase of Helicobacter pylori switches from a peroxide reductase to a molecular chaperone function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Alkylhydroperoxide reductase of Helicobacter pylori as a biomarker for gastric patients with different pathological manifestations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Crystal structure of alkyl hydroperoxide-reductase (AhpC) from Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Effect of differential N-linked and O-linked mannosylation on recognition of fungal antigens by dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Mannose receptor-targeted vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Importance of the host genetic background on immune responses to Helicobacter pylori infection and therapeutic vaccine efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Absence of CD4+CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Post-immunisation gastritis and Helicobacter infection in the mouse: a long term study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Gastric Helicobacter species infection in murine and gerbil models: comparative analysis of effects of H. pylori and H. felis on gastric epithelial cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

A good practice guide to the administration of substances and removal of blood, including routes and volumes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Enhanced cultivation of Helicobacter pylori in liquid media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Local immunoglobulin G antibodies in the stomach may contribute to immunity against Helicobacter infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Protection against Helicobacter pylori infection in mongolian gerbil by intragastric or intramuscular administration of H. pylori multicomponent vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

13C-urea breath test results in pigs challenged with Helicobacter pylori or other urease producing bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Clearance of Helicobacter pylori infection through immunization: the site of T cell activation contributes to vaccine efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Effects of fungal N- and O-linked mannosylation on the immunogenicity of model vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Antibody-independent protective mucosal immunity to gastric helicobacter infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Characteristics of glycosylated streptokinase secreted from Pichia pastoris: enhanced resistance of SK to proteolysis by glycosylation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

The neutrophil-activating protein of Helicobacter pylori (HP-NAP) as an immune modulating agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Vaccination of mice against H pylori induces a strong Th-17 response and immunity that is neutrophil dependent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Proinflammatory cytokine gene expression in the stomach correlates with vaccine-induced protection against Helicobacter pylori infection in mice: an important role for interleukin-17 during the effector phase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Vaccine-induced immunity against Helicobacter pylori in the absence of IL-17A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Local recall responses in the stomach involving reduced regulation and expanded help mediate vaccine-induced protection against Helicobacter pylori in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Childhood Helicobacter pylori infection in a murine model: maternal transmission and eradication by systemic immunization using bacterial antigen-aluminium hydroxide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Systemic immunization with urease protects mice against Helicobacter pylori infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

The quest for a vaccine against Helicobacter pylori: how to move from mouse to man?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

Catalase, a novel antigen for Helicobacter pylori vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Role of the host in pathogenesis of Helicobacter-associated gastritis: H. felis infection of inbred and congenic mouse strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2012.04.002

1 reference

6 February 2018

PubMed ID

22512976

1 reference

6 February 2018